MX2009008561A - Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. - Google Patents
Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.Info
- Publication number
- MX2009008561A MX2009008561A MX2009008561A MX2009008561A MX2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A MX 2009008561 A MX2009008561 A MX 2009008561A
- Authority
- MX
- Mexico
- Prior art keywords
- growth hormone
- cell proliferative
- proliferative disorders
- treating cell
- hormone secretagogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90160907P | 2007-02-13 | 2007-02-13 | |
| PCT/US2008/001748 WO2008100448A2 (en) | 2007-02-13 | 2008-02-08 | Method of treating cell proliferative disorders using growth hormone secretagogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009008561A true MX2009008561A (es) | 2010-01-15 |
Family
ID=39690677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009008561A MX2009008561A (es) | 2007-02-13 | 2008-02-08 | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX341660B (es) * | 2010-02-26 | 2016-08-29 | Raqualia Pharma Inc | Agonista del receptor de ghrelina para el tratamiento de caquexia. |
| JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| PT3466930T (pt) | 2013-02-08 | 2022-08-19 | Gen Mills Inc | Produto alimentar com baixo teor de sódio |
| AP2017009772A0 (en) * | 2014-09-04 | 2017-02-28 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| US20220323430A1 (en) | 2019-08-30 | 2022-10-13 | Helsinn Healthcare Sa | Methods of manufacturing anamorelin tablets having improved stability |
| CA3162166A1 (en) | 2019-12-02 | 2021-06-10 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112112A (en) * | 1993-12-23 | 2000-06-29 | Novo Nordisk As | Peptides with growth hormone releasing properties and pharmaceutical compositions containing them |
| CZ195098A3 (cs) * | 1995-12-22 | 1998-10-14 | Novo Nordisk A/S | Sloučeniny uvolňující růstový hormon |
| US5922770A (en) * | 1996-07-22 | 1999-07-13 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6566334B1 (en) * | 1997-02-06 | 2003-05-20 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Short amphipathic peptides with activity against bacteria and intracellular pathogens |
| US6286927B1 (en) * | 1997-12-25 | 2001-09-11 | Canon Kabushiki Kaisha | Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted |
| US6494563B2 (en) * | 1997-12-25 | 2002-12-17 | Canon Kabushiki Kaisha | Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted |
| US6083908A (en) * | 1998-01-16 | 2000-07-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6303620B1 (en) * | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6124263A (en) | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| US6919315B1 (en) | 1998-06-30 | 2005-07-19 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6566337B1 (en) * | 1998-11-03 | 2003-05-20 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| UA73530C2 (uk) | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| DE60140285D1 (de) * | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
| ES2330193T3 (es) * | 2000-06-07 | 2009-12-07 | Merck Serono Sa | Hormona de crecimiento humano para estimular la movilizacion de celulas madre hematopoyeticas pluripotentes. |
| WO2002070511A1 (en) * | 2001-03-02 | 2002-09-12 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
| US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| JP2007531769A (ja) * | 2004-03-30 | 2007-11-08 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法 |
| ES2602789T3 (es) * | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
-
2008
- 2008-02-08 WO PCT/US2008/001748 patent/WO2008100448A2/en active Application Filing
- 2008-02-08 EA EA200970764A patent/EA200970764A1/ru unknown
- 2008-02-08 JP JP2009549593A patent/JP2010518158A/ja active Pending
- 2008-02-08 EP EP08725389.4A patent/EP2134341B1/en not_active Not-in-force
- 2008-02-08 AU AU2008216789A patent/AU2008216789A1/en not_active Abandoned
- 2008-02-08 CA CA002677813A patent/CA2677813A1/en not_active Abandoned
- 2008-02-08 MX MX2009008561A patent/MX2009008561A/es not_active Application Discontinuation
- 2008-02-08 CN CN200880011801A patent/CN101686966A/zh active Pending
- 2008-02-08 KR KR1020097017491A patent/KR20090112720A/ko not_active Application Discontinuation
- 2008-02-11 US US12/069,533 patent/US20080207640A1/en not_active Abandoned
- 2008-02-13 TW TW097104956A patent/TWI450719B/zh active
-
2009
- 2009-08-12 IL IL200367A patent/IL200367A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008100448A2 (en) | 2008-08-21 |
| EP2134341A2 (en) | 2009-12-23 |
| CN101686966A (zh) | 2010-03-31 |
| AU2008216789A1 (en) | 2008-08-21 |
| KR20090112720A (ko) | 2009-10-28 |
| IL200367A0 (en) | 2010-04-29 |
| EP2134341A4 (en) | 2011-08-17 |
| TW200914019A (en) | 2009-04-01 |
| WO2008100448A3 (en) | 2008-10-23 |
| US20080207640A1 (en) | 2008-08-28 |
| EP2134341B1 (en) | 2015-06-17 |
| JP2010518158A (ja) | 2010-05-27 |
| CA2677813A1 (en) | 2008-08-21 |
| EA200970764A1 (ru) | 2010-04-30 |
| TWI450719B (zh) | 2014-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010378A (es) | Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento. | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| MX2009008561A (es) | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. | |
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| WO2012082718A3 (en) | 3-methanesulfonylpropionitrile for treating inflammation and pain | |
| IN2014KN00948A (US07846941-20101207-C00217.png) | ||
| GEP20135933B (en) | Compounds as bradykinin b1 antagonists | |
| WO2010149578A3 (en) | Novel biphenyl and phenyl-pyridine amides | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX360030B (es) | Metodos para tratar el trastorno bipolar. | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| WO2012078757A3 (en) | Combination for breast cancer therapy with hsp90 inhibitory compounds | |
| MX2012002387A (es) | Aminas de triazol fusionadas como moduladores p2x7. | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| MY191352A (en) | Aldosterone synthase inhibitors | |
| IN2012DN02816A (US07846941-20101207-C00217.png) | ||
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |